124937-52-6 Usage
Description
Tolterodine tartrate, also known as Detrol LA, is a tartrate salt of tolterodine and functions as a competitive muscarinic receptor antagonist. It is a tertiary muscarinic antagonist primarily used to manage urinary frequency, urgency, and incontinence in detrusor instability. Tolterodine tartrate is characterized by its white-to-off-white crystalline powder appearance.
Uses
Used in Pharmaceutical Industry:
Tolterodine tartrate is used as a therapeutic agent for the treatment of overactive bladder with symptoms of urge urinary incontinence and urgency. It acts as a competitive antagonist of muscarinic (M) receptors, effectively managing the symptoms by blocking the muscarinic receptors and reducing involuntary muscle contractions in the bladder.
Used in Overactive Bladder Treatment:
Tolterodine tartrate is used as a medication to alleviate the symptoms of overactive bladder, such as urinary frequency, urgency, and incontinence. By targeting muscarinic receptors (M1 through M5) with high affinity, it helps to reduce the involuntary contractions of the bladder, providing relief to patients suffering from these conditions.
Therapeutic Function
Anticholinergic
Biological Activity
tolterodine tartrate (detrol la) is a tartrate salt of tolterodine that is a competitive muscarinic receptor antagonist.
Clinical Use
Selective vasopressin V2 -receptor antagonist: Treatment of hyponatraemia secondary to SIADH To slow the progression of autosomal dominant polycystic kidney disease (ADPKD)
Drug interactions
Potentially hazardous interactions with other drugs
Anti-arrhythmics: increased risk of ventricular
arrhythmias with amiodarone, disopyramide and
flecainide; increased risk of antimuscarinic side
effects with disopyramide.
Antifungals: avoid concomitant use with itraconazole
and ketoconazole.
Antivirals: avoid concomitant use with
fosamprenavir, indinavir, lopinavir, ritonavir and
saquinavir.
Beta-blockers: increased risk of ventricular
arrhythmias with sotalol.
Metabolism
Metabolised mainly by the cytochrome P450 isoenzyme CYP3A4. Eliminated mainly by the faecal route
Check Digit Verification of cas no
The CAS Registry Mumber 124937-52-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,2,4,9,3 and 7 respectively; the second part has 2 digits, 5 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 124937-52:
(8*1)+(7*2)+(6*4)+(5*9)+(4*3)+(3*7)+(2*5)+(1*2)=136
136 % 10 = 6
So 124937-52-6 is a valid CAS Registry Number.
InChI:InChI=1/C22H31NO.C4H6O6/c1-16(2)23(17(3)4)14-13-20(19-9-7-6-8-10-19)21-15-18(5)11-12-22(21)24;5-1(3(7)8)2(6)4(9)10/h6-12,15-17,20,24H,13-14H2,1-5H3;1-2,5-6H,(H,7,8)(H,9,10)/t20-;/m1./s1
124937-52-6Relevant articles and documents
Ligand-Phospholipid Conjugation: A Versatile Strategy for Developing Long-Acting Ligands That Bind to Membrane Proteins by Restricting the Subcellular Localization of the Ligand
Kawamura, Shuhei,Ito, Yoshihiko,Hirokawa, Takatsugu,Hikiyama, Eriko,Yamada, Shizuo,Shuto, Satoshi
, p. 4020 - 4029 (2018/05/07)
We hypothesized that if drug localization can be restricted to a particular subcellular domain where their target proteins reside, the drugs could bind to their target proteins without being metabolized and/or excreted, which would significantly extend the half-life of the corresponding drug-target complex. Thus, we designed ligand-phospholipid conjugates in which the ligand is conjugated with a phospholipid through a polyethylene glycol linker to restrict the subcellular localization of the ligand in the vicinity of the lipid bilayer. Here, we present the design, synthesis, pharmacological activity, and binding mode analysis of ligand-phospholipid conjugates with muscarinic acetylcholine receptors as the target proteins. These results demonstrate that ligand-phospholipid conjugation can be a versatile strategy for developing long-acting ligands that bind to membrane proteins in drug discovery.
PROCESS FOR THE PREPARATION OF N,N-DIISOPROPYL-3-(2-HYDROXY-5-METHYLPHENYL)- 3-PHENYL PROPYLAMINE AND ITS SALTS STARTING FROM A NOVEL INTERMEDIATE
-
, (2012/08/07)
The invention concerns an improved process for the preparation of tolterodine (N,N-diisopropyl-3-(2-hydroxy-5-methylphenyl)-3-phenyl propyl amine) and its salts, in particular for the preparation of the tartrate salt, and more particularly for the (+)-(R) enantiomer of tolterodine L-tartrate, starting from a novel intermediate, N,N-diisopropyl-3-(2-hydroxy-5-methylphenyl)-3- phenyl-2-propenamide, which can be used as pure Z or E isomer or as a mixture of Z and E isomers. When the target is the preparation of the enantiomer (R)-(+)-(N,N- diisopropyl-3-(2-hydroxy-5-methylphenyl)-3-phenylpropylamine) and diastereomeric crystallization of suitable compound is applied, the present invention covers also the use of racemisation of undesired (S)-(-)- (N,N-diisopropyl-3-(2-hydroxy-5-methylphenyl)-3 -phenyl propylamine) enantiomer and its recycle in the process.
A PROCESS FOR THE PREPARATION OF TOLTERODINE TARTRATE
-
Paragraph 213-222, (2010/09/03)
The present invention relates to provide a process for the preparation of (+)-(R)-Tolterodine-L-tartrate, comprises a step of aminating hydroxyl protected 3-(2-methoxy-5-methylphenyl)-3-phenyl propanol of formula (V) with diisopropylamine in the presence of water to obtain N, N-diisopropyl-3-(2-methoxy-5-methylphenyl)-3-phenylpropyl amine of formula (VI).